Mirum Phase III data: Livmarli significantly reduces itch, bile acids in ultra-rare cholestatic liver diseases

 

• Phase 3 EXPAND study of LIVMARLI (maralixibat) in ultra-rare cholestatic liver diseases met its primary endpoint.
• Detailed results included patients with biliary atresia, expanding evidence for Livmarli in additional ultra-rare cholestatic liver diseases.
• Mirum plans a U.S. sNDA for Livmarli label expansion in the first half of 2027.

https://finviz.com/stock?t=MIRM&p=d